



Woad, Kathryn J. and Robinson, Robert S. (2016) Luteal angiogenesis and its control. *Theriogenology* . ISSN 0093-691X (In Press)

Access from the University of Nottingham repository:

<http://eprints.nottingham.ac.uk/33233/1/1-s2%20-S0093691X16300747-main%20accepted%20manuscript.pdf>

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution Non-commercial No Derivatives licence and may be reused according to the conditions of the licence. For more details see: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

Accepted Manuscript

Luteal angiogenesis and its control

Kathryn J. Woad, Robert S. Robinson

PII: S0093-691X(16)30074-7

DOI: [10.1016/j.theriogenology.2016.04.035](https://doi.org/10.1016/j.theriogenology.2016.04.035)

Reference: THE 13615

To appear in: *Theriogenology*



Please cite this article as: Woad KJ, Robinson RS, Luteal angiogenesis and its control, *Theriogenology* (2016), doi: 10.1016/j.theriogenology.2016.04.035.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Luteal angiogenesis and its control.**

2 Kathryn J Woad^{1,2} & Robert S Robinson¹.

3 ¹School of Veterinary Medicine and Science, Sutton Bonington campus, University of
4 Nottingham, Leicestershire, LE12 5RD, UK.

5

6 ²Corresponding author: Dr Kathryn Woad

7 Tel: (44) 115 9516554; Fax (44) 115 9516415; e-mail: katie.woad@nottingham.ac.uk

8

9

10

11 **Abstract**

12 Angiogenesis, the formation of new blood vessels from pre-existing ones, is critical to luteal
13 structure and function; In addition, it is a complex and tightly regulated process. Not only
14 does rapid and extensive angiogenesis occur to provide the corpus luteum (CL) with an
15 unusually high blood flow and support its high metabolic rate, but in the absence of
16 pregnancy the luteal vasculature must rapidly regress to enable the next cycle of ovarian
17 activity. This review describes a number of the key endogenous stimulatory and inhibitory
18 factors, which act in a delicate balance to regulate luteal angiogenesis and ultimately luteal
19 function. *In vitro* luteal angiogenesis cultures have demonstrated critical roles for fibroblast
20 growth factor 2 (FGF2) in endothelial cell proliferation and sprouting, whilst other factors
21 such as vascular endothelial growth factor (VEGFA) and platelet derived growth factor
22 (PDGF) were important modulators in the control of luteal angiogenesis. Post-transcriptional
23 regulation by small non-coding micro-RNAs, is also likely to play a central role in the
24 regulation of luteal angiogenesis. Appropriate luteal angiogenesis requires the coordinated
25 activity of numerous factors expressed by several cell types at different times and this
26 review will also describe the role of perivascular pericytes and the importance of vascular
27 maturation and stability. It is hoped that a better understanding of the critical processes
28 underlying the transition from follicle to CL, and subsequent luteal development will benefit
29 the management of luteal function in the future.

30 **Key words:** ovary, corpus luteum; angiogenesis; vasculature; FGF2, VEGFA

31 **1. The importance of luteal angiogenesis**

32 The corpus luteum (CL) is a transient endocrine structure that is critical for the
33 establishment and maintenance of pregnancy in mammals. It is formed from the remnants
34 of the ruptured follicle post-ovulation and undergoes remarkable growth, differentiation
35 and remodelling. Often compared to fast growing tumours, the dramatic growth of the CL is
36 reliant upon angiogenesis, or the formation of new blood vessels from pre-existing vessels
37 from the follicular theca layer [1].

38 The crucial importance of angiogenesis to luteal structure and function has been
39 demonstrated in a number of species, including domestic ruminants. For example, the
40 experimental blockade of angiogenesis resulted in reduced CL number, limited luteal
41 vasculature and marked inhibition of steroidogenesis in rats [2]. Similarly, intra-follicular or
42 systemic administration of anti-angiogenic factors (e.g. VEGFA trap) to non-human primates
43 altered ovulation, reduced endothelial cell proliferation in the CL and inhibited
44 progesterone production [3, 4]. Furthermore, intra-luteal anti-angiogenic treatments
45 reduced CL volume and plasma progesterone concentrations and disrupted normal luteal
46 gene expression in the cow [5].

47 Transgenic mouse models which have targeted angiogenic signals have similarly resulted in
48 both diminished ovarian vasculature and fertility [6]. In addition, poor vascularisation has
49 been linked to inadequate luteal function, such as that observed following ovulation
50 induction in women and livestock, and in the peripubertal and postpartum periods in
51 domestic animals [7-9].

52 2. Establishment of the luteal vasculature

53 Luteal angiogenesis originates from the developing follicle. Early follicles (primordial and
54 primary) have no established vascular supply of their own. Rather, blood vessels develop as
55 follicles undergo continued growth, with endothelial cell recruitment occurring from the
56 ovarian stromal compartment. Follicular vessels remain within the thecal layer and are
57 excluded from the granulosa cell layer by the basement membrane which divides the two.
58 Following the luteinising hormone (LH) surge, the breakdown of the basement membrane
59 enables blood vessels to invade the granulosa layer as cellular remodelling begins [10]. The
60 continuation of development from ovulatory follicle to corpus luteum therefore also
61 suggests that appropriate follicular development, including blood vessel formation, may be
62 critical to the success of subsequent luteinisation [11]. Indeed, recent evidence showed
63 that follicular vascularity is positively correlated with luteal blood flow and progesterone
64 production [12]. Furthermore, the degree of follicular vascularisation has been associated
65 positively with follicular dominance and negatively with atresia [13].

66 The early events of luteinisation are accompanied by marked cell proliferation, with
67 proliferation indices around 40% [14, 15]. Critically, the majority of mitotic cells are not
68 steroidogenic luteal cells, but rather they are from the microvasculature [14, 15]. Indeed,
69 endothelial cells are a prominent cell-type within the corpus luteum, occupying around 15%
70 of luteal tissue volume, and representing around 50% of all cells at mid-cycle [16]. Such an
71 extensive contribution to the mature luteal tissue ensures that nearly all steroidogenic cells
72 are in immediate contact with at least one capillary [17].

73

74 3. The response to LH

75 Ovulation and early luteinisation are characterised by complex changes in gene expression,
76 with perhaps hundreds of genes differentially expressed [18-20]. The molecular response to
77 an ovulatory dose of LH is also rapid, with the first changes in gene expression occurring
78 within 30 minutes. Genes associated with ovulation have been implicated in inflammation,
79 steroid and prostanoid pathways, proteolytic disruption of the tissue matrix and protection
80 against oxidative stress [18]. Others have demonstrated that luteinisation is accompanied by
81 a switch from a molecular signature of proliferation and metabolism to one where cell
82 migration and angiogenesis predominate [19].

83 More recently, the potential importance of post-transcriptional regulation has come to the
84 fore [21]. Small non-coding RNAs such as microRNAs (miRNAs) function primarily as
85 negative regulators of gene expression and are now thought to be key regulators of ovarian
86 function, including the follicular-luteal transition [22]. Mice deficient for the miRNA
87 processing enzyme Dicer displayed luteal insufficiency that was associated with poor
88 angiogenesis and reduced luteal vascular density [23]. In the sheep ovary, a total of 17
89 miRNAs were identified whose abundance varied significantly between follicular and luteal
90 phases and are potential important regulators of luteinisation [24]. This included decreased
91 levels of miR-503 (a known angiogenesis inhibitor) during early luteinisation. Interestingly,
92 the theca cell layer was the major site of miRNA expression, with vascular components of
93 the thecal layer expected to be key targets of miRNA regulation, as has been shown in other
94 tissues [25].

95

96 4. Control of luteal angiogenesis

97 4.1. Stimulatory factors

98 Follicular fluid accumulates angiogenic factors that are likely to provide an initial stimulus to
99 post-ovulatory angiogenesis [26]. Corpora lutea subsequently produce pro-angiogenic
100 factors throughout the luteal phase and into pregnancy [27, 28] and their actions can result
101 in endothelial cell proliferation, migration and tubule formation *in vitro* and *in vivo*. A
102 significant number of factors are mediators of angiogenesis [29], including vascularisation of
103 the CL. Key amongst these are the heparin-binding factors, namely vascular endothelial
104 growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2).

105 VEGFA is a potent endothelial mitogen, which exists as one of several isoforms [30] as a
106 result of the alternative splicing of a single VEGFA gene. VEGFA₁₆₅ is the predominant
107 (human) protein isoform produced by a variety of cells and is so named due to its 165 amino
108 acids, following cleavage of the signal sequence. Molecular species with 121, 189, and 206
109 amino acids are also described, plus several rare species such as VEGFA₁₄₅ and VEGFA₁₈₃; in
110 the cow, each isoform is one amino acid shorter [31]. All isoforms contain domains that
111 enable receptor binding and all are biologically active. The various isoforms do exhibit
112 different biochemical properties however, with some predominantly soluble species, such
113 as VEGFA₁₂₁ and VEGFA₁₆₅ and others (VEGFA₁₈₉ and VEGFA₂₀₆) significantly cell or matrix-
114 bound until released following proteolysis of the ECM [30].

115 The presence of *VEGFA* mRNA and protein has been demonstrated in the ovary of many
116 species [32-36]. In bovine antral follicles, VEGFA was localised to granulosa cells, and cells of
117 the theca layer, and increased with follicular growth and development (Figure 1; [36]). In the
118 bovine CL, *VEGFA* mRNA was detected throughout the luteal phase and during pregnancy,

119 but decreased in the late luteal phase [37], and luteal steroidogenic cells were the major
120 cellular site of VEGFA protein expression (Figure 1; [37]).

121 Members of the VEGF family interact with several receptors and co-receptors to exert their
122 actions [30]. VEGFA binds to the related receptors VEGFR1 (Flt1) and VEGFR2 (KDR or Flk1),
123 with the mitogenic and angiogenic responses to VEGFA largely mediated via VEGFR2. These
124 tyrosine kinase receptors are expressed on the surface of endothelial cells, including those
125 of the ovary [38]. Indeed, VEGFR1 and R2 were expressed by microvascular endothelial cells
126 derived from the bovine CL [38]. Others have detected VEGFR2 in bovine luteal cells and
127 smooth muscle cells, as well as endothelial cells by immunohistochemistry [39]. VEGFR1
128 expression did not vary according to luteal stage, whilst VEGFR2 mRNA was most highly
129 expressed in the early [37] to mid [39] CL.

130 As eluded to earlier, neutralisation of VEGF by several routes and in several species
131 including the cow, caused marked reductions in luteal vascularisation and progesterone
132 production [4, 5, 40]. In addition to its ability to stimulate an angiogenic response, VEGFA
133 infusion also stimulated progesterone production by micro-dialysed bovine CL *in vitro* [41].
134 VEGFA is therefore considered essential to luteal structure and function.

135 Fibroblast growth factor 2 is also a prominent regulator of luteal angiogenesis. Often
136 overlooked in importance relative to VEGFA, early work in the sheep and cow demonstrated
137 the significant inhibition of endothelial mitogenic activity following immuno-neutralisation
138 of FGF2 from luteal-conditioned media [28, 42]. In addition, the neutralisation of FGF2 *in*
139 *vivo* resulted in luteal disruption, with CL volume, steroidogenic function and gene
140 expression significantly diminished [5]. Indeed, in the cow, luteal FGF2 concentrations have
141 been shown to be more dynamic around the follicular-luteal transition than VEGFA,

142 suggestive of a more critical role for FGF2 in early luteinisation [26]. FGF2 protein levels
143 were significantly elevated in early bovine CL (day 1-2) and declined with subsequent luteal
144 development [26].

145 In order to further dissect the regulation of luteal angiogenesis in the cow, we established a
146 novel, physiologically relevant *in vitro* culture system that mimics both luteal steroidogenic
147 function and angiogenesis [43]. The use of luteal endothelial cells is critical, since
148 endothelial cells and angiogenic responses are known to differ between tissues and
149 microenvironments [44]. In the bovine luteal angiogenesis culture system early CL (days 1-
150 4) are dissected from the ovary, dissociated enzymatically and mixed luteal cells (including
151 steroidogenic, endothelial (EC), fibroblast and perivascular cells) are then plated on
152 fibronectin-coated wells. Luteal cells are grown in culture for up to 9 days, in the presence
153 of endothelial-specific media, plus or minus angiogenic support (VEGFA and/or FGF2).
154 During this time, steroidogenic cells produce progesterone in a LH-responsive manner [43].
155 In addition, endothelial cells can be stimulated to undergo characteristic tubule-like growth,
156 resulting in the formation of complex and extensive highly-branched EC networks (Figure 2).
157 Using this system, the degree of bovine EC network formation was stimulated by both
158 VEGFA and FGF2 [43, 45]. FGFR1 inhibition, via treatment with SU5402 throughout the
159 culture period, dramatically reduced the total area of EC networks by 94% versus controls,
160 as a result of reductions in the number of individual EC networks and a tendency to reduce
161 the size of each network [45]. In contrast, the inhibition of VEGFR2 signalling was more
162 modest, reducing EC area by around 60% [45]. Strikingly, the response to FGFR1 inhibition
163 was observed despite the presence of VEGFA treatments, further supporting the critical role
164 of FGF2 in luteal endothelial network formation [45, 46].

165 FGFR1 inhibition was further utilised to elucidate which stage(s) of luteal angiogenesis are
166 most dependent upon FGF2 stimulation [46]. In particular, the earliest stages of
167 angiogenesis were most sensitive to FGFR1 inhibition *in vitro*, as evidenced by a 64%
168 reduction in total EC networks following SU5402 treatment on days 0-3 and by around 81%
169 following treatment on days 3-6 versus controls. Days 3-6 in culture is a period of intense
170 reorganisation, when EC begin to sprout from EC islands and form tubule-like structures
171 (Figure 2). Further analysis revealed that FGFR1 inhibition on days 3-6 resulted in a marked
172 reduction in EC network branch points. This suggested a critical role for FGF2 in endothelial
173 sprouting, as well as endothelial cell proliferation [46]. Indeed, FGF2 has been shown to
174 promote vascular branching in several systems: FGF2 increased the density and branching of
175 the microvessels of the chorioallantoic membrane [47] and transgenic mice with disrupted
176 FGFR1 signalling displayed retinal phenotypes with reduced capillary density and branching
177 [48]. Furthermore, FGF2 dose-dependently increased the degree of EC branching in a bovine
178 luteinising follicular culture system [49].

179 Endothelial cell sprouting is a complex process, involving coordinated cell migration and
180 phenotypic specialization in response to directional cues [50]. Early in the process, certain
181 endothelial cells emerge as tip cells, characterised by numerous cellular extensions or
182 filopodia which sense the surrounding environment, whilst others remain at the stalks of
183 the vascular sprouts. Recent data suggesting that FGFR1 participates in tip cell function and
184 filopodia formation via interactions with the cytoskeletal protein Nostrin, which is involved
185 in membrane dynamics, further supports a role for FGF2 in EC sprouting [51].

186 Hypoxia is potent stimulator of angiogenesis in numerous situations. There is evidence that
187 hypoxic conditions found in the early CL might upregulate FGF2 expression and hence

188 stimulate luteal angiogenesis [52]. Protein levels of the hypoxia-induced transcription factor,
189 HIF1A were greatest in the early bovine CL and decreased thereafter [53] in a pattern similar
190 to FGF2 [54]. Furthermore, in human umbilical vein endothelial cells in response to hypoxia,
191 upregulation of HIF1A resulted in branching morphogenesis via induction of FGF2 [55].
192 Positive feedback between HIF1A and FGF2 has also been reported [52].

193 The role of FGF2 in regulating both luteal angiogenesis and the production of the maternal
194 recognition signal, interferon tau, in ruminants [56] has made it a valid candidate gene in
195 the search for genetic markers associated with reproductive efficiency. The association
196 between FGF2 gene variants (single nucleotide polymorphisms; SNP) and a range of fertility-
197 related traits has been investigated in several studies. In Holstein cows, embryo survival *in*
198 *vitro* was significantly associated with the genotype of the intronic SNP11646 (rs110937773;
199 FGF2 intron 1) [57]. However, no significant associations were observed between this or
200 another polymorphism (SNP23; rs208883803) and a range of fertility traits, including those
201 potentially influenced by luteal function or cyclicity such as number of inseminations per
202 conception, calving to conception interval or conception rate [58] and Woad et al,
203 unpublished.

204 The delta-Notch signalling pathway has been implicated in the determination of cell fate
205 and patterning associated with endothelial cell sprouting and vascular development [59,
206 60]. Endothelial cells express Notch receptors and their ligands (Delta-like ligand 1, 4 and
207 Jagged1), and the balance of signalling determines tip versus stalk cell fate, with tip cells
208 preferentially expressing Dll4, whilst stalk cells express predominantly Jagged1. Notch
209 receptors and ligands have been localised to the follicular and luteal vasculature [61-63],
210 including in the bovine CL (Robinson et al., unpublished). In the marmoset, inhibition of Dll4

211 in the periovulatory period, led to increased angiogenesis in the early luteal phase.
212 However, the vasculature that was formed was dysregulated and non-functional, resulting
213 in decreased progesterone production [64]. In the bovine luteal angiogenesis culture
214 system, the addition of γ -secretase inhibitors to block Notch signalling reduced EC network
215 formation (Robinson et al., unpublished).

216 4.2. Inhibitory factors

217 The control of angiogenesis requires the appropriate balance of both positive and negative
218 signals. In the follicle, angiogenesis is thought to be actively restrained until after ovulation,
219 thus preventing premature vascularisation. Pigment epithelium derived factor (PEDF) is a
220 recently described, physiological inhibitor of angiogenesis, with ovarian influence [65]. PEDF
221 is secreted by mouse and human granulosa cells and this secretion was sharply decreased
222 by progesterone treatment. It is inhibitory in angiogenesis assays, and the loss of PEDF led
223 to accelerated angiogenesis *in vitro*.

224 Thrombospondins (THBS1 and 2) are anti-angiogenic factors with many mechanisms of
225 inhibition. THBS1 can bind FGF2 and this sequestration [66] then inhibits its pro-angiogenic
226 actions. The modulation of angiogenesis by thrombospondins may be particularly important
227 for luteal regression. For example, in the sheep CL, THBS1 expression was upregulated
228 during luteolysis [67]. Furthermore, prostaglandin PGF2 α -induced increased expression of
229 THBS1 and 2, and their receptor CD36 in the bovine CL in a stage dependant manner, with
230 the PG-refractory CL showing no upregulation [68]. Critically, luteal angiogenesis was
231 inhibited in response to these factors even in the presence of pro-angiogenic FGF2, and
232 inhibition was also observed in the absence of FGF2 [68].

233 Alterations in angiogenic support (VEGFA and FGF2), increased angiogenic inhibition
234 (thrombospondins, pentraxin 3 and transforming growth factor B1) and changes in luteal
235 blood flow (endothelin-1 and nitric oxide) can all occur in response to luteolytic-PG and will
236 contribute to the eventual disruption of the microvasculature and subsequent luteal
237 regression [68-71].

238 The VEGFA system has anti-angiogenic components, several of which have been implicated
239 in ovarian function. The complex splicing of the *VEGFA* mRNA, leads to the production of an
240 alternative family of VEGFA_{xxx}b isoforms (where xxx refers to the number of amino acids),
241 which are generated by distal splice site utilisation in exon 8 [72]. In the porcine CL,
242 VEGFA164b was detected at low levels throughout the luteal phase [73]. In the marmoset
243 monkey, VEGFA165b comprised around 65% of total VEGFA in CL-bearing ovaries [6].
244 Overexpression of VEGFA165b in mice reduced follicular development, leading to lower CL
245 number, reduced luteal size and decreased microvascular density and stability [6]. In
246 contrast, VEGFA164b mRNA was not detected in the CL at any stage in the cow [74].

247 VEGFA activity can be further modified by soluble receptor isoforms, sVEGFR1 and sVEGFR2,
248 which act as VEGF binding proteins. In the bovine CL, soluble receptors were found
249 throughout the luteal phase. Indeed, sVEGFR1 was more than 100 times as abundant as the
250 membrane bound receptor [74]. The functional significance of this observation remains to
251 be elucidated.

252 Vasohibin1 (VASH1) is a further factor with negative regulatory potential [75]. In the bovine
253 CL, It is expressed primarily in the luteal endothelial cells, is induced by VEGFA and then
254 inhibits VEGFA actions in a classical negative feedback mechanism. It was suggested that

255 VASH1 might act to fine tune pro-angiogenic signals and prevent inappropriate
256 vascularisation [75]; however its exact role remains to be demonstrated.

257 **5. Stabilising the vasculature**

258 In addition to extensive and rapid vascularisation, the corpus luteum also requires newly
259 formed vessels to undergo maturation and stabilisation in order to be fully functional. The
260 angiopoietins (ANGPT1 and ANGPT2) have particular importance in vessel stability [29].

261 They are considered important partners for VEGFA and act primarily through the Tie2
262 receptor. ANGPT2 is an endogenous Tie2 antagonist [76], that results in vessel
263 destabilisation and the ratio of ANGPT1/ANGPT2 is therefore considered of critical
264 importance to vessel fate. During the follicular-luteal transition, the destabilising effect of
265 ANGPT2 is thought to maintain vascular plasticity, hence modifying responsiveness to pro-
266 angiogenic signals such as VEGFA [76].

267 Pericytes (perivascular mural cells) are important constituents of microvessels, with key
268 roles in vascular development and function, including the stabilisation and maturation of
269 vessels [77, 78]. The recruitment of pericytes to the blood vessel wall and their subsequent
270 interactions with endothelial cells are critically regulated by platelet derived growth factor
271 (PDGF) signalling via the PDGF receptor B (PDGFRB). The inhibition of pericyte-recruitment
272 around ovulation reduced the number of luteal structures formed in rodents [79, 80] and
273 induced widespread luteal haemorrhage, suggestive of an obligatory requirement for
274 pericyte involvement in appropriate luteal angiogenesis. Furthermore, inhibition of PDGF
275 signalling *in vitro* reduced endothelial cell network formation in our bovine luteal
276 angiogenesis culture system and the networks were most sensitive to receptor blockade
277 during the early stages of angiogenesis [45]. Smooth muscle actin-positive mural cells

278 (putative pericytes) were found closely associated with endothelial cells *in vitro* (Figure 3;
279 [49]). Mural cells were localised both as integral components of EC islands and on the
280 borders of the islands. During the follicular-luteal transition in the cow, pericytes appeared
281 to migrate ahead of EC from the theca layer into the luteinising granulosa cells. This was
282 potentially to guide sprouting processes and/or lay down ECM such as fibronectin [10, 54].
283 Similarly, in culture, mural cells were found at the tips of endothelial sprouts (Figure 3; [49]).
284 This might indicate that pericytes play an active role at all stages of luteal angiogenesis.

285 **6. Conclusion**

286 Angiogenesis is critical to the structure and function of the corpus luteum. It is a complex
287 process that is under exquisite control, requiring the interaction of numerous factors and
288 several cell types during a period of remarkable dynamism. Whilst there is good evidence
289 for several critical regulators with both pro- and anti-angiogenic functions, further
290 investigation of the mechanisms of luteal angiogenesis is essential for improving our
291 understanding of luteal function

292

293

294 **Acknowledgements**

295 This work has been funded by BBSRC, Pfizer, Society for Reproduction and Fertility Academic
296 Scholarship and University of Nottingham. We greatly appreciate the technical assistance of
297 staff at the University of Nottingham without which this work would not have been possible.

298

299

300

- 301 [1] Reynolds L, Redmer D. Growth and Development of the Corpus Luteum. *J Reprod Fertil Suppl.*
302 1999;54:181-91.
- 303 [2] Ferrara N, Chen H, Davis-Smyth T, Gerber HP, Nguyen TN, Peers D, et al. Vascular Endothelial
304 Growth Factor Is Essential for Corpus Luteum Angiogenesis. *Nat Med.* 1998;4:336-40.
- 305 [3] Hazzard TM, Xu FH, Stouffer RL. Injection of Soluble Vascular Endothelial Growth Factor Receptor
306 1 into the Preovulatory Follicle Disrupts Ovulation and Subsequent Luteal Function in Rhesus
307 Monkeys. *Biol Reprod.* 2002;67:1305-12.
- 308 [4] Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, et al. Suppression of Luteal
309 Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor.
310 *Endocrinology.* 2000;141:995-1000.
- 311 [5] Yamashita H, Kamada D, Shirasuna K, Matsui M, Shimizu T, Kida K, et al. Effect of Local
312 Neutralization of Basic Fibroblast Growth Factor or Vascular Endothelial Growth Factor by a Specific
313 Antibody on the Development of the Corpus Luteum in the Cow. *Mol Reprod Dev.* 2008;75:1449-56.
- 314 [6] Qiu Y, Seager M, Osman A, Castle-Miller J, Bevan H, Tortonese DJ, et al. Ovarian Vegf(165)B
315 Expression Regulates Follicular Development, Corpus Luteum Function and Fertility. *Reproduction.*
316 2012;143:501-11.
- 317 [7] Garverick HA, Smith MF. Mechanisms Associated with Subnormal Luteal Function. *J Anim Sci.*
318 1986;62 (Suppl. 2):92-105.
- 319 [8] Smith GD, Sawyer HR, Mirando MA, Griswold MD, Sadhu A, Reeves JJ. Steady-State Luteinizing
320 Hormone Receptor Messenger Ribonucleic Acid Levels and Endothelial Cell Composition in Bovine
321 Normal- and Short-Lived Corpora Lutea. *Biol Reprod.* 1996;55:902-9.
- 322 [9] Keisler DH, Keisler LW. Formation and Function of GnRH-Induced Subnormal Corpora Lutea in
323 Cyclic Ewes. *J Reprod Fertil.* 1989;87:265-73.
- 324 [10] Amselgruber WM, Schafer M, Sinowatz F. Angiogenesis in the Bovine Corpus Luteum: An
325 Immunocytochemical and Ultrastructural Study. *Anatomia, Histologia, Embryologia.* 1999;28:157-66.

- 326 [11] Inskip EK. Preovulatory, Postovulatory, and Postmaternal Recognition Effects of
327 Concentrations of Progesterone on Embryonic Survival in the Cow. *J Anim Sci.* 2004;82 E-Suppl:E24-
328 39.
- 329 [12] de Tarso SGS, Gastal GDA, Bashir ST, Gastal MO, Apgar GA, Gastal EL. Follicle Vascularity
330 Coordinates Corpus Luteum Blood Flow and Progesterone Production. *Reprod Fertil Dev.* 2015:-.
- 331 [13] Moor RM, Seamark RF. Cell Signaling, Permeability, and Microvasculatory Changes During Antral
332 Follicle Development in Mammals. *J Dairy Sci.* 1986;69:927-43.
- 333 [14] Christenson LK, Stouffer RL. Proliferation of Microvascular Endothelial Cells in the Primate
334 Corpus Luteum During the Menstrual Cycle and Simulated Early Pregnancy. *Endocrinology.*
335 1996;137:367-74.
- 336 [15] Jablonka-Shariff A, Grazul-Bilska AT, Redmer DA, Reynolds LP. Growth and Cellular Proliferation
337 of Ovine Corpora Lutea Throughout the Estrous Cycle. *Endocrinology.* 1993;133:1871-9.
- 338 [16] O'Shea JD, Rodgers RJ, D'Occhio MJ. Cellular Composition of the Cyclic Corpus Luteum of the
339 Cow. *J Reprod Fertil.* 1989;85:483-7.
- 340 [17] Zheng J, Redmer DA, Reynolds LP. Vascular Development and Heparin-Binding Growth Factors in
341 the Bovine Corpus Luteum at Several Stages of the Estrous Cycle. *Biol Reprod.* 1993;49:1177-89.
- 342 [18] Espey LL, Richards JS. Temporal and Spatial Patterns of Ovarian Gene Transcription Following an
343 Ovulatory Dose of Gonadotropin in the Rat. *Biol Reprod.* 2002;67:1662-70.
- 344 [19] Agca C, Ries JE, Kolath SJ, Kim J-H, Forrester LJ, Antoniou E, et al. Luteinization of Porcine
345 Preovulatory Follicles Leads to Systematic Changes in Follicular Gene Expression. *Reproduction.*
346 2006;132:133-45.
- 347 [20] Sarit F, Ada D, Abraham A. Ovarian Transcriptomes as a Tool for a Global Approach of Genes
348 Modulated by Gonadotropic Hormones in Human Ovarian Granulosa Cells. *Endocr.* 2005;26:259-65.
- 349 [21] Krol J, Loedige I, Filipowicz W. The Widespread Regulation of MicroRNA Biogenesis, Function and
350 Decay. *Nat Rev Genet.* 2010;11:597-610.

- 351 [22] Donadeu FX, Schauer SN, Sontakke SD. Involvement of Mirnas in Ovarian Follicular and Luteal
352 Development. *J Endocrinol.* 2012;215:323-34.
- 353 [23] Otsuka M, Zheng M, Hayashi M, Lee J-D, Yoshino O, Lin S, et al. Impaired MicroRNA Processing
354 Causes Corpus Luteum Insufficiency and Infertility in Mice. *J Clin Invest.* 2008;118:1944-54.
- 355 [24] McBride D, Carré W, Sontakke SD, Hogg CO, Law A, Donadeu FX, et al. Identification of Mirnas
356 Associated with the Follicular–Luteal Transition in the Ruminant Ovary. *Reproduction.* 2012;144:221-
357 33.
- 358 [25] Suárez Y, Sessa WC. MicroRNAs as Novel Regulators of Angiogenesis. *Circul Res.* 2009;104:442-
359 54.
- 360 [26] Robinson RS, Nicklin LT, Hammond AJ, Schams D, Hunter MG, Mann GE. Fibroblast Growth
361 Factor 2 Is More Dynamic Than Vascular Endothelial Growth Factor a During the Follicle-Luteal
362 Transition in the Cow. *Biol Reprod.* 2007;77:28-36.
- 363 [27] Redmer DA, Grazul AT, Kirsch JD, Reynolds LP. Angiogenic Activity of Bovine Corpora Lutea at
364 Several Stages of Luteal Development. *J Reprod Fertil.* 1988;82:627-34.
- 365 [28] Grazul-Bilska AT, Reynolds LP, Slinger WD, Redmer DA. Production of Heparin-Binding
366 Angiogenic Factor(S) by Bovine Corpora Lutea During Pregnancy. *J Anim Sci.* 1992;70:254-62.
- 367 [29] Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-Specific Growth
368 Factors and Blood Vessel Formation. *Nature.* 2000;407:242-8.
- 369 [30] Ferrara N, Gerber H-P, LeCouter J. The Biology of Vegf and Its Receptors. *Nat Med.* 2003;9:669-
370 76.
- 371 [31] Tischer E, Gospodarowicz D, Mitchell R, Silva M, Schilling J, Lau K, et al. Vascular Endothelial
372 Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family. *Biochem*
373 *Biophys Res Commun.* 1989;165:1198-206.
- 374 [32] Phillips HS, Hains J, Leung DW, Ferrara N. Vascular Endothelial Growth Factor Is Expressed in Rat
375 Corpus Luteum. *Endocrinology.* 1990;127:965-7.

- 376 [33] Redmer DA, Dai Y, Li J, Charnock-Jones DS, Smith SK, Reynolds LP, et al. Characterization and
377 Expression of Vascular Endothelial Growth Factor (Vegf) in the Ovine Corpus Luteum. *J Reprod Fertil.*
378 1996;108:157-65.
- 379 [34] Laitinen M, Ristimäki A, Honkasalo M, Narko K, Paavonen K, Ritvos O. Differential Hormonal
380 Regulation of Vascular Endothelial Growth Factors Vegf, Vegf-B, and Vegf-C Messenger Ribonucleic
381 Acid Levels in Cultured Human Granulosa-Luteal Cells. *Endocrinology.* 1997;138:4748-56.
- 382 [35] Wulff C, Dickson SE, Duncan WC, Fraser HM. Angiogenesis in the Human Corpus Luteum:
383 Simulated Early Pregnancy by Hcg Treatment Is Associated with Both Angiogenesis and Vessel
384 Stabilization. *Hum Reprod.* 2001;16:2515-24.
- 385 [36] Greenaway J, Gentry PA, Feige J-J, LaMarre J, Petrik JJ. Thrombospondin and Vascular
386 Endothelial Growth Factor Are Cyclically Expressed in an Inverse Pattern During Bovine Ovarian
387 Follicle Development. *Biol Reprod.* 2005;72:1071-8.
- 388 [37] Berisha B, Schams D, Kosmann M, Amselgruber W, Einspanier R. Expression and Tissue
389 Concentration of Vascular Endothelial Growth Factor, Its Receptors, and Localization in the Bovine
390 Corpus Luteum During Estrous Cycle and Pregnancy. *Biol Reprod.* 2000;63:1106-14.
- 391 [38] Gabler C, Plath-Gabler A, Killian GJ, Berisha B, Schams D. Expression Pattern of Fibroblast
392 Growth Factor (Fgf) and Vascular Endothelial Growth Factor (Vegf) System Members in Bovine
393 Corpus Luteum Endothelial Cells During Treatment with Fgf-2, Vegf or Oestradiol. *Reprod Domest*
394 *Anim.* 2004;39:321-7.
- 395 [39] Hünigen H, Bisplinghoff P, Plendl J, Bahramsoltani M. Vascular Dynamics in Relation to
396 Immunolocalisation of Vegf-a, Vegfr-2 and Ang-2 in the Bovine Corpus Luteum. *Acta Histochem.*
397 2008;110:462-72.
- 398 [40] Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, et al. The Vascular Endothelial Growth
399 Factor (Vegf)/Vegf Receptor 2 Pathway Is Critical for Blood Vessel Survival in Corpora Lutea of
400 Pregnancy in the Rodent. *Endocrinology.* 2005;146:1301-11.

- 401 [41] Kobayashi S, Berisha B, Amselgruber WM, Schams D, Miyamoto A. Production and Localisation
402 of Angiotensin II in the Bovine Early Corpus Luteum: A Possible Interaction with Luteal Angiogenic
403 Factors and Prostaglandin F₂α. *J Endocrinol.* 2001;170:369-80.
- 404 [42] Grazul-Bilska AT, Redmer DA, Killilea SD, Kraft KC, Reynolds LP. Production of Mitogenic
405 Factor(S) by Ovine Corpora Lutea Throughout the Estrous Cycle. *Endocrinology.* 1992;130:3625-32.
- 406 [43] Robinson RS, Hammond AJ, Mann GE, Hunter MG. A Novel Physiological Culture System That
407 Mimics Luteal Angiogenesis. *Reproduction.* 2008;135:405-13.
- 408 [44] McCarthy SA, Kuzu I, Gatter KC, Bicknell R. Heterogeneity of the Endothelial Cell and Its Role in
409 Organ Preference of Tumour Metastasis. *Trends Pharmacol Sci.* 1991;12:462-7.
- 410 [45] Woad KJ, Hammond AJ, Hunter M, Mann GE, Hunter MG, Robinson RS. Fgf2 Is Crucial for the
411 Development of Bovine Luteal Endothelial Networks in Vitro. *Reproduction.* 2009;138:581-8.
- 412 [46] Woad KJ, Hunter MG, Mann GE, Laird M, Hammond AJ, Robinson RS. Fibroblast Growth Factor 2
413 Is a Key Determinant of Vascular Sprouting During Bovine Luteal Angiogenesis. *Reproduction.*
414 2012;143:35-43.
- 415 [47] Parsons-Wingerter P, Elliott KE, Clark JI, Farr AG. Fibroblast Growth Factor-2 Selectively
416 Stimulates Angiogenesis of Small Vessels in Arterial Tree. *Arterioscl Throm Vas.* 2000;20:1250-6.
- 417 [48] Rousseau Bt, Dubayle D, Sennlaub F, Jeanny J-C, Costet P, Bikfalvi A, et al. Neural and Angiogenic
418 Defects in Eyes of Transgenic Mice Expressing a Dominant-Negative Fgf Receptor in the Pigmented
419 Cells. *Exp Eye Res.* 2000;71:395-404.
- 420 [49] Laird M, Woad KJ, Hunter MG, Mann GE, Robinson RS. Fibroblast Growth Factor 2 Induces the
421 Precocious Development of Endothelial Cell Networks in Bovine Luteinising Follicular Cells. *Reprod*
422 *Fertil Dev.* 2013;25:372-86.
- 423 [50] Eilken HM, Adams RH. Dynamics of Endothelial Cell Behavior in Sprouting Angiogenesis. *Curr*
424 *Opin Cell Biol.* 2010;22:617-25.

- 425 [51] Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, et al. The F-Bar Protein Nostrin
426 Participates in Fgf Signal Transduction and Vascular Development. *The EMBO Journal*. 2012;31:3309-
427 22.
- 428 [52] Meidan R, Klipper E, Zalman Y, Yalu R. The Role of Hypoxia-Induced Genes in Ovarian
429 Angiogenesis. *Reprod Fertil Dev*. 2013;25:343-50.
- 430 [53] Nishimura R, Okuda K. Hypoxia Is Important for Establishing Vascularization During Corpus
431 Luteum Formation in Cattle. *J Reprod Dev*. 2010;56:110-6.
- 432 [54] Robinson RS, Woad KJ, Hammond AJ, Laird M, Hunter MG, Mann GE. Angiogenesis and Vascular
433 Function in the Ovary. *Reproduction*. 2009;138:869-81.
- 434 [55] Calvani M, Rapisarda A, Uranchimeg B, Shoemaker RH, Melillo G. Hypoxic Induction of an Hif-
435 1 α -Dependent Bfgf Autocrine Loop Drives Angiogenesis in Human Endothelial Cells. *Blood*.
436 2006;107:2705-12.
- 437 [56] Michael DD, Alvarez IM, Ocón OM, Powell AM, Talbot NC, Johnson SE, et al. Fibroblast Growth
438 Factor-2 Is Expressed by the Bovine Uterus and Stimulates Interferon- γ Production in Bovine
439 Trophectoderm. *Endocrinology*. 2006;147:3571-9.
- 440 [57] Khatib H, Maltecca C, Monson RL, Schutzkus V, Wang X, Rutledge JJ. The Fibroblast Growth
441 Factor 2 Gene Is Associated with Embryonic Mortality in Cattle. *J Anim Sci*. 2008;86:2063-7.
- 442 [58] Oikonomou G, Michailidis G, Kougioumtzis A, Avdi M, Banos G. Effect of Polymorphisms at the
443 Stat5a and Fgf2 Gene Loci on Reproduction, Milk Yield and Lameness of Holstein Cows. *Res Vet Sci*.
444 2011;91:235-9.
- 445 [59] Benedito R, Hellstrom M. Notch as a Hub for Signaling in Angiogenesis. *Exp Cell Res*.
446 2013;319:1281-8.
- 447 [60] De Smet F, Segura I, De Bock K, Hohensinner PJ, Carmeliet P. Mechanisms of Vessel Branching
448 Filopodia on Endothelial Tip Cells Lead the Way. *Arterioscl Throm Vas*. 2009;29:639-49.

- 449 [61] Vorontchikhina MA, Zimmermann RC, Shawber CJ, Tang HY, Kitajewski J. Unique Patterns of
450 Notch1, Notch4 and Jagged1 Expression in Ovarian Vessels During Folliculogenesis and Corpus
451 Luteum Formation. *Gene Expr Patterns*. 2005;5:701-9.
- 452 [62] Murta D, Batista M, Silva E, Trindade A, Mateus L, Duarte A, et al. Differential Expression of
453 Notch Component and Effector Genes During Ovarian Follicle and Corpus Luteum Development
454 During the Oestrous Cycle. *Reprod Fertil Dev*. 2014;doi:10.1071/RD13399.
- 455 [63] Jovanovic VP, Sauer CM, Shawber CJ, Gomez R, Wang X, Sauer MV, et al. Intraovarian Regulation
456 of Gonadotropin-Dependent Folliculogenesis Depends on Notch Receptor Signaling Pathways Not
457 Involving Delta-Like Ligand 4 (Dll4). *Reprod Biol Endocrinol*. 2013;11.
- 458 [64] Fraser HM, Hastings JM, Allan D, Morris KD, Rudge JS, Wiegand SJ. Inhibition of Delta-Like
459 Ligand 4 Induces Luteal Hypervascularization Followed by Functional and Structural Luteolysis in the
460 Primate Ovary. *Endocrinology*. 2012;153:1972-83.
- 461 [65] Chuderland D, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Komsky A, Satchi-Fainaro R, et al.
462 Hormonal Regulation of Pigment Epithelium-Derived Factor (Pef) in Granulosa Cells. *Mol Human*
463 *Reprod*. 2013;19:72-81.
- 464 [66] Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, et al. Non-Peptidic
465 Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors: An Integrated Strategy for the
466 Development of New Antiangiogenic Compounds. *J Biol Chem*. 2010;285:8733-42.
- 467 [67] Romero JJ, Antoniazzi AQ, Smirnova NP, Webb BT, Yu F, Davis JS, et al. Pregnancy-Associated
468 Genes Contribute to Antiluteolytic Mechanisms in Ovine Corpus Luteum. *Physiol Genomics*.
469 2013;45:1095-108.
- 470 [68] Zalman Y, Klipper E, Farberov S, Mondal M, Wee G, Folger JK, et al. Regulation of Angiogenesis-
471 Related Prostaglandin F2alpha-Induced Genes in the Bovine Corpus Luteum. *Biol Reprod*.
472 2012;86:92.

- 473 [69] Hou X, Arvisais EW, Jiang C, Chen DB, Roy SK, Pate JL, et al. Prostaglandin F2alpha Stimulates the
474 Expression and Secretion of Transforming Growth Factor B1 Via Induction of the Early Growth
475 Response 1 Gene (Egr1) in the Bovine Corpus Luteum. *Mol Endocrinol.* 2008;22:403-14.
- 476 [70] Shirasuna K, Asaoka H, Acosta TJ, Wijayagunawardane MP, Ohtani M, Hayashi M, et al. Real-
477 Time Relationships in Intraluteal Release among Prostaglandin F2alpha, Endothelin-1, and
478 Angiotensin II During Spontaneous Luteolysis in the Cow. *Biol Reprod.* 2004;71:1706-11.
- 479 [71] Shirasuna K, Sasahara K, Matsui M, Shimizu T, Miyamoto A. Prostaglandin F2alpha Differentially
480 Affects Mrna Expression Relating to Angiogenesis, Vasoactivation and Prostaglandins in the Early and
481 Mid Corpus Luteum in the Cow. *The Journal of reproduction and development.* 2010;56:428-36.
- 482 [72] Harper SJ, Bates DO. Vegf-a Splicing: The Key to Anti-Angiogenic Therapeutics? *Nat Rev Cancer.*
483 2008;8:880-7.
- 484 [73] Ribeiro LA, Bacci ML, Seren E, Tamanini C, Forni M. Characterization and Differential Expression
485 of Vascular Endothelial Growth Factor Isoforms and Receptors in Swine Corpus Luteum Throughout
486 Estrous Cycle. *Mol Reprod Dev.* 2007;74:163-71.
- 487 [74] Guzman A, Macias-Valencia R, Fierro-Fierro F, Gutierrez CG, Rosales-Torres AM. The Corpora
488 Lutea Proangiogenic State of Vegf System Components Is Turned to Antiangiogenic at the Later
489 Phase of the Oestrous Cycle in Cows. *Animal.* 2015;9:301-7.
- 490 [75] Shirasuna K, Kobayashi A, Nitta A, Nibuno S, Sasahara K, Shimizu T, et al. Possible Action of
491 Vasohibin-1 as an Inhibitor in the Regulation of Vascularization of the Bovine Corpus Luteum.
492 *Reproduction.* 2012;143:491-500.
- 493 [76] Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-
494 2, a Natural Antagonist for Tie2 That Disrupts in Vivo Angiogenesis. *Science.* 1997;277:55-60.
- 495 [77] Armulik A, Abramsson A, Betsholtz C. Endothelial/Pericyte Interactions. *Circul Res.* 2005;97:512-
496 23.
- 497 [78] Bergers G, Song S. The Role of Pericytes in Blood-Vessel Formation and Maintenance. *Neuro-*
498 *Oncology.* 2005;7:452-64.

499 [79] Kuhnert F, Tam BYY, Sennino B, Gray JT, Yuan J, Jocson A, et al. Soluble Receptor-Mediated
500 Selective Inhibition of Vegfr and Pdgfr Beta Signaling During Physiologic and Tumor Angiogenesis.
501 Proc Natl Acad Sci U S A. 2008;105:10185-90.

502 [80] Sler LS, Taylor CC. Platelet-Derived Growth Factors and Receptors in the Rat Corpus Luteum:
503 Localization and Identification of an Effect on Luteogenesis. Biol Reprod. 2007;76:391-400.

504

505


506 **Figure 1:** The localisation of VEGFA in **(A)** a dominant follicle and **(B)** the corpus luteum (CL) in the
507 cow. There was intense staining of VEGFA in the granulosa (G) layer (brown staining, arrowhead).
508 VEGFA was also present, albeit at much lower levels in the theca (T) layer. **(B)** shows the intense
509 staining of VEGFA in the steroidogenic cells (arrowhead) of the day 5 CL. There was some variation in
510 the stain intensity between different steroidogenic cells across the whole section. The scale bar
511 represents 200µm. Robinson et al., unpublished observations.

512 **Figure 2:** Time course of bovine luteal angiogenesis *in vitro*, showing a bovine ovary bearing **(A)** an
513 early corpus luteum (arrow) selected for culture, and subsequent endothelial cell growth between
514 12 h and 9 days. Endothelial cells were immuno-localised by von Willebrand factor staining (brown)
515 after **(B)** 12 and **(C)** 18 h (day 1) and then every 24 h; day 2 **(D and E)**, day 3 **(F)**, day 4 **(G)**, day 5 **(H)**,
516 day 6 **(I)**, day 7 **(J)**, day 8 **(K)** and day 9 **(L)**. Bar represents 100 µm. Adapted from [46].

517 **Figure 3:** The temporal-spatial interactions between endothelial cells and perivascular mural cell in
518 the bovine luteal-endothelial co-culture system, on **(A)** day 6 or **(B)** day 9 of culture. The endothelial
519 cells (EC) were immuno-stained with von Willebrand (green) while the mural cells were identified by
520 smooth muscle actin immunohistochemistry (red). The nucleus was counterstained with DAPI (blue).
521 On day 6, the EC were present in large islands of cells containing several hundred cells. Inter-
522 dispersed within these EC islands and around the edge were mural cells. On day 9, the EC had a
523 much more network-like appearance with multiple sprouts projecting away from the centre of the
524 EC island. Again, mural cells were often closely associated with the EC networks. On both days 6 and
525 9, mural cells were often present at the tips of sprouting EC (arrowhead). The scale bar represents
526 200µm. Robinson, Woad et al., unpublished observations.

527

528



1


2 **Figure 1:**

3

4

5

6



7


8

9 **Figure 2:**

10

11

12



13

14

15 **Figure 3:**

16

17 **Figure 1:** The localisation of VEGFA in **(A)** a dominant follicle and **(B)** the corpus luteum (CL) in the
18 cow. There was intense staining of VEGFA in the granulosa (G) layer (brown staining, arrowhead).
19 VEGFA was also present, albeit at much lower levels in the theca (T) layer. **(B)** shows the intense
20 staining of VEGFA in the steroidogenic cells (arrowhead) of the day 5 CL. There was some variation in
21 the stain intensity between different steroidogenic cells across the whole section. The scale bar
22 represents 200µm. Robinson et al., unpublished observations.

23 **Figure 2:** Time course of bovine luteal angiogenesis *in vitro*, showing a bovine ovary bearing **(A)** an
24 early corpus luteum (arrow) selected for culture, and subsequent endothelial cell growth between
25 12 h and 9 days. Endothelial cells were immuno-localised by von Willebrand factor staining (brown)
26 after **(B)** 12 and **(C)** 18 h (day 1) and then every 24 h; day 2 **(D and E)**, day 3 **(F)**, day 4 **(G)**, day 5 **(H)**,
27 day 6 **(I)**, day 7 **(J)**, day 8 **(K)** and day 9 **(L)**. Bar represents 100 µm. Adapted from [46].

28 **Figure 3:** The temporal-spatial interactions between endothelial cells and perivascular mural cell in
29 the bovine luteal-endothelial co-culture system, on **(A)** day 6 or **(B)** day 9 of culture. The endothelial
30 cells (EC) were immuno-stained with von Willebrand (green) while the mural cells were identified by
31 smooth muscle actin immunohistochemistry (red). The nucleus was counterstained with DAPI (blue).
32 On day 6, the EC were present in large islands of cells containing several hundred cells. Inter-
33 dispersed within these EC islands and around the edge were mural cells. On day 9, the EC had a
34 much more network-like appearance with multiple sprouts projecting away from the centre of the
35 EC island. Again, mural cells were often closely associated with the EC networks. On both days 6 and
36 9, mural cells were often present at the tips of sprouting EC (arrowhead). The scale bar represents
37 200µm. Robinson, Woad et al., unpublished observations.

38